Mehrdad Faizi

Mehrdad Faizi

Auto-generated profile, based on publicly available information

Mehrdad Faizi

Department of Pharmacology and Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2004 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
AAali almasirad
ali almasirad
STSayyed A. Tabatabai
Sayyed A. Tabatabai
MFMehrdad Faizi
Mehrdad Faizi
AKAbbas Kebriaeezadeh
Abbas Kebriaeezadeh
NMNazila Mehrabi
Nazila Mehrabi
ASAbbas Shafiee
Abbas Shafiee

1 April 2005 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
AZAfshin Zarghi
Afshin Zarghi
STSayyed A. Tabatabai
Sayyed A. Tabatabai
MFMehrdad Faizi
Mehrdad Faizi
AAAvideh Ahadian
Avideh Ahadian
PNParisa Navabi
Parisa Navabi
ASAbbas Shafiee
Abbas Shafiee

30 August 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PBPatrick L. Bader
Patrick L. Bader
MFMehrdad Faizi
Mehrdad Faizi
LKLeo H. Kim
Leo H. Kim
SOScott F. Owen
Scott F. Owen
MTMichael R. Tadross
Michael R. Tadross
MSMehrdad Shamloo
Mehrdad Shamloo
Autism and autism spectrum disorder (ASD) typically arise from a mixture of environmental influences and multiple genetic alterations. In some rare cases, such as Timothy syndrome (TS), a specific mutation in a single gene can be sufficient to generate autism or ASD in most patients, potentially offering insights into the etiology of autism in general. Both variants of TS (the milder TS1 and the more severe TS2) arise from missense mutations in alternatively spliced exons that cause the same G406R replacement in the Ca V 1.2 L-type calcium channel. We generated a TS2-like mouse but found that heterozygous (and homozygous) animals were not viable. However, heterozygous TS2 mice that were allowed to keep an inverted neomycin cassette (TS2-neo) survived through adulthood. We attribute the survival to lowering of expression of the G406R L-type channel via transcriptional interference, blunting deleterious effects of mutant L-type channel overactivity, and addressed potential effects of altered gene dosage by studying Ca V 1.2 knockout heterozygotes. Here we present a thorough behavioral phenotyping of the TS2-neo mouse, capitalizing on this unique opportunity to use the TS mutation to model ASD in mice. Along with normal general health, activity, and anxiety level, TS2-neo mice showed markedly restricted, repetitive, and perseverative behavior, altered social behavior, altered ultrasonic vocalization, and enhanced tone-cued and contextual memory following fear conditioning. Our results suggest that when TS mutant channels are expressed at levels low enough to avoid fatality, they are sufficient to cause multiple, distinct behavioral abnormalities, in line with the core aspects of ASD.

4 July 2012 in Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
AKAlexander M. Kleschevnikov
Alexander M. Kleschevnikov
PBPavel V. Belichenko
Pavel V. Belichenko
MFMehrdad Faizi
Mehrdad Faizi
LJLucia F. Jacobs
Lucia F. Jacobs
KHKhin Htun
Khin Htun
WMWilliam C. Mobley
William C. Mobley
Cognitive impairment in Down syndrome (DS) is characterized by deficient learning and memory. Mouse genetic models of DS exhibit impaired cognition in hippocampally mediated behavioral tasks and reduced synaptic plasticity of hippocampal pathways. Enhanced efficiency of GABAergic neurotransmission was implicated in those changes. We have recently shown that signaling through postsynaptic GABAB receptors is significantly increased in the dentate gyrus of Ts65Dn mice, a genetic model of DS. Here we examined a role for GABAB receptors in cognitive deficits in DS by defining the effect of selective GABAB receptor antagonists on behavior and synaptic plasticity of adult Ts65Dn mice. Treatment with the GABAB receptor antagonist CGP55845 restored memory of Ts65Dn mice in the novel place recognition, novel object recognition, and contextual fear conditioning tasks, but did not affect locomotion and performance in T-maze. The treatment increased hippocampal levels of brain-derived neurotrophic factor, equally in 2N and Ts65Dn mice. In hippocampal slices, treatment with the GABAB receptor antagonists CGP55845 or CGP52432 enhanced long-term potentiation (LTP) in the Ts65Dn DG. The enhancement of LTP was accompanied by an increase in the NMDA receptor-mediated component of the tetanus-evoked responses. These findings are evidence for a contribution of GABAB receptors to changes in hippocampal-based cognition in the Ts65Dn mouse. The ability to rescue cognitive performance through treatment with selective GABAB receptor antagonists motivates studies to further explore the therapeutic potential of these compounds in people with DS.

18 November 2009 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ASA. Salehi
A. Salehi
MFM. Faizi
M. Faizi
DCD. Colas
D. Colas
JVJ. Valletta
J. Valletta
JLJ. Laguna
J. Laguna
WMW. C. Mobley
W. C. Mobley
Down syndrome (trisomy 21) is the most common cause of mental retardation in children and leads to marked deficits in contextual learning and memory. In rodents, these tasks require the hippocampus and are mediated by several inputs, particularly those originating in the locus coeruleus. These afferents mainly use norepinephrine as a transmitter. To explore the basis for contextual learning defects in Down syndrome, we examined the Ts65Dn mouse model. These mice, which have three copies of a fragment of mouse chromosome 16, exhibited significant deficits in contextual learning together with dysfunction and degeneration of locus coeruleus neurons. However, the postsynaptic targets of innervation remained responsive to noradrenergic receptor agonists. Indeed, despite advanced locus coeruleus degeneration, we were able to reverse contextual learning failure by using a prodrug for norepinephrine called l-threo-3,4-dihydroxyphenylserine, or xamoterol, a β1-adrenergic receptor partial agonist. Moreover, an increased gene dosage of App, in the context of Down syndrome, was necessary for locus coeruleus degeneration. Our findings raise the possibility that restoring norepinephrine-mediated neurotransmission could reverse cognitive dysfunction in Down syndrome.

1 August 2011 in Neurobiology of Disease
Verified
Journal Article
Closed access
MFMehrdad Faizi
Mehrdad Faizi
PBPatrick L. Bader
Patrick L. Bader
CTChristine Tun
Christine Tun
AEAngelo Encarnacion
Angelo Encarnacion
AKAlexander Kleschevnikov
Alexander Kleschevnikov
DBDenise Briggs
Denise Briggs